Guangyong Zou - Department of Ecotourism, Shanghai Business School

基本信息

浏览量：75

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 303 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Differential Efficacy of Medical Therapies for Ulcerative Colitis According to Disease Extent: Patient-Level Analysis from Multiple Randomized Controlled Trials

Sudheer K. Vuyyuru,Christopher Ma,Tran M. Nguyen,Guangyong Zou,Laurent Peyrin-Biroulet,Silvio Danese,Parambir Dulai,Neeraj Narula,Siddharth Singh,Vipul Jairath

ECLINICALMEDICINE (2024)

引用0浏览0WOS引用

Does Prescribing Apixaban or Rivaroxaban Versus Warfarin for Patients Diagnosed with Atrial Fibrillation Save Health System Costs? A Multivalued Treatment Effects Analysis

Michael Situ,Ute I. Schwarz,Guangyong Zou,Eric McArthur,Richard B. Kim,Amit X. Garg,Sisira Sarma

EUROPEAN JOURNAL OF HEALTH ECONOMICS（2024）

引用1浏览0WOS引用

Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn's Disease

Reena Khanna,Brian G. Feagan,Guangyong Zou,Larry W. Stitt,John W. D. Mcdonald,Brian Bressler,Remo Panaccione,Lisa M. Shackelton,Tanja VanViegen,Edward Loftus Jr,Marco Daperno,Vipul Jairath,Geert D'Haens,William J. Sandborn

INFLAMMATORY BOWEL DISEASES（2024）

引用0浏览0WOS引用

Responsiveness of Different Disease Activity Indices in Moderate-to-severe Ulcerative Colitis

Virginia Solitano,Remo Panaccione,Bruce E. Sands,Zhongya Wang,Malcolm Hogan,Guangyong Zou,Laurent Peyrin-Biroulet,Silvio Danese, Linda J. Cornfield,Brian G. Feagan,Siddharth Singh,Vipul Jairath,Christopher Ma

Med (2024)

引用0浏览0WOS引用

Personalized (N-of-1) Clinical Trials for Inflammatory Bowel Disease: Opportunities and Challenges

Sailish Honap,Guangyong Zou,Silvio Danese,Laurent Peyrin-Biroulet,Vipul Jairath

Clinical Gastroenterology and Hepatology（2024）

引用0浏览0WOS引用

DOP11 Disease Clearance after 16 Weeks of Treatment with Vedolizumab in Patients with Moderate to Severe Ulcerative Colitis: an Interim Analysis from the VERDICT Trial

Vipul Jairath,Guang Yong Zou,Shashi Adsul,Jean‐Frédéric Colombel,Geert R. D’Haens, M Freire,Gordon W. Moran,Laurent Peyrin‐Biroulet,William J. Sandborn,Sebastian Scheer,Simon Travis,Séverine Vermeire,Jurij Hanžel,Christopher Ma,Rocío Sedaño, Peter F. Sheridan,N Arya,Melanie Beaton,Peter Bossuyt,Silvio Danese, Daniel Green,William R. Harlan,M Horynski,Jarosław Kierkuś,Adam Kopoń,Maria Kłopocka,Rima Petronienė, M S Silverberg, Ł Wolański,Brian G. Feagan

Journal of Crohn's and colitisno. Supplement_1 (2024): i92-i93

引用0浏览0引用

905 DISEASE CLEARANCE AFTER 16 WEEKS OF TREATMENT WITH VEDOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM THE VERDICT TRIAL

V. Jairath,G. Zou,S. Adsul,J. F. Colombel,G. R. D'Haens,M. Freire,G. W. Moran,L. Peyrin-Biroulet,W. J. Sandborn,S. Sebastian,S. Travis,S. Vermeire,J. Hanzel,C. Ma,R. Sedano, P. Sheridan,N. Arya,M. Beaton,P. Bossuyt,S. Danese, D. Green, W. Harlan,M. Horynski,J. Kierkus, A. Kopon,M. Klopocka,R. Petroniene, M. S. Silverberg, L. Wolanski,B. G. Feagan

Gastroenterologyno. 5 (2024): S-218

引用0浏览0引用

Identification of Immune Cell Markers Associated with Ulcerative Colitis Histological Disease Activity in Colonic Biopsies

Pavine L. C. Lefevre,Zhongya Wang,Wendy Teft,Guangyong Zou,Tanja Van Viegen,Bryan Linggi,Vipul Jairath,Brian G. Feagan,Rish K. Pai,Niels Vande Casteele

JOURNAL OF CLINICAL PATHOLOGY（2024）

引用0浏览0WOS引用

Vedolizumab to Prevent Postoperative Recurrence of Crohn's Disease (REPREVIO): a Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial

Geert D'Haens,Carlos Taxonera, Antonio Lopez-Sanroman, Pilar Nos,Silvio Danese,Alessandro Armuzzi,Xavier Roblin,Laurent Peyrin-Biroulet,Rachel West,Wout G N Mares,Marjolijn Duijvestein, Krisztina B Gecse,Brian G Feagan,Guangyong Zou, Melanie S Hulshoff,Aart Mookhoek, Lotte Oldenburg,Esmé Clasquin,Yoram Bouhnik,David Laharie

The Lancet Gastroenterology & Hepatology (2024)

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn